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Background: CD4þCD25þFoxp3þ regulatory T (Treg) cells mediate immunosuppression and play an
important role in tumor immune evasion. Studies have demonstrated that this cell population represents
an aging-related change. It is not clear whether this change leads to higher tumor incidence in the
elderly. We investigated changes in CD4þCD25þFoxp3þ Treg cells in relation to aging and tumor
incidence.
Methods: We set up a Lewis lung cancermodel with 26 C57BL/6 female mice. The animals were divided into
six groups: young healthy, middle-aged healthy, elderly healthy, young tumor, middle-aged tumor and
elderly tumor.We evaluated changes in CD4þCD25þFoxp3þTreg cells in the spleen of all animals using aﬂow
cytometry method. Levels of Foxp3mRNA in splenocytes were measured using a real-time RT-PCRmethod.
Results: The CD4þCD25þFoxp3þ/CD4þ T cell ratio (t¼ 2.23, p¼ 0.032) and Foxp3 mRNA levels (t¼ 3.26,
p¼ 0.0042) were higher in the tumor groups than in the healthy groups. In the healthy groups, there was
a signiﬁcant increase in CD4þCD25þFoxp3þ Treg cells on aging (F¼ 47.70, p¼ 0.000); elderly mice had
a signiﬁcantly greater population of CD4þCD25þFoxp3þ Treg cells in spleen compared to the younger
groups. The highest population was observed in the elderly tumor group. The same trend was evident for
Foxp3 mRNA (F¼ 6.56, p¼ 0.0090).
Conclusions: The results suggest a close relationship between changes in CD4þCD25þFoxp3þ Treg cells
and aging and lung tumor genesis and development.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
With aging, the incidence and prevalence of tumor increase1e3,
suggesting an intimate relationship between aging and tumors4,5.
In other words, many mechanisms involved in the aging process
share molecular mechanisms implicated in carcinogenesis6. The
existence of relationships between aging and the risk of tumor
development is not very well understood. From an immunology
perspective, a tumor suppresses the immune response of the body
and develops in vivo via many pathological processes, such as
immunity escape, toleration and suppression7. Changes in the
immunity system with aging further provide favorable conditions
for tumor escape, so there is a higher incidence of tumors in the
elderly. An understanding of the contribution of immunose-
nescence to tumor development and progression may help interest.
ﬁliated Hospital of Soochow
iwan Society of Geriatric Emergendesigning better interventions for tumors in the elderly. Recent
evidence demonstrated that regulatory T cell (Treg)-mediated
immunosuppression is a crucial tumor immune evasion mecha-
nism and contributes to the failure of tumor immunotherapy8e11.
This regulatory capacities has been attributed to several different
cell types, but the most characterized group is CD4þCD25þFoxp3þ
Treg cells, which increase with aging12. We presume that increases
in CD4þCD25þFoxp3þ Treg cells are responsible for the high tumor
incidence in the elderly. Recently, lung tumor, as the highest rate of
the malignant tumors13, rises exponentially with aging14. In this
study, we set up a Lewis lung cancer model in animals of different
ages. We investigated changes in CD4þCD25þFoxp3þ Treg cells in
healthy and tumor model groups with aging and explored the
relation between immunosenescence and lung tumors.
2. Materials and methods
2.1. Cell lines
Transplantable Lewis lung carcinoma (LLC) cells (Cell Bank,
Shanghai Scientiﬁc Research Institute, Chinese Academy of Sciences)cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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glucose content supplemented with 10% fetal bovine serum, 100 U/
mL penicillin, 100 mg/mL streptomycin sulfate, and 0.25 mg/mL
amphotericin B in a 5% CO2 atmosphere at 37 C.
2.2. Animals and tumor model
C57BL/6 female mice (n¼ 36, Institute of Laboratory Animals,
Shanghai SLAK, Certiﬁcate of Quality No. 2007000504834) were
divided into six groups: 4-week healthy (young healthy, YH), 6-
month healthy (middle-aged healthy, MH), 20-month healthy
(elderly healthy, EH), 4-week tumor (young tumor, YT), 6-month
tumor (middle-aged tumor, MT) and 20-month tumor (elderly
tumor, ET), with six mice in each group. Mice were maintained
under speciﬁc pathogen-free conditions and provided with food
and water ad libitum. All animals were housed for 1 week and
maintained under standard conditions prior to experimentation.
All animal procedures were performed in accordancewith the rules
of the local Ethics Committee and the guidelines established by the
Animal Care Committee, which approved the study (No. 2091116).
All tumor groups were injected subcutaneously with 0.1 mL of LLC
cells (2106 cells) in the left forelimb. The healthy groups were
injected with the same amount of phosphate-buffered saline (PBS)
in the same site. After implantation, tumor growth dynamics was
monitored every 2 days. The tumor long diameter (L) and short
diameter (W) were used to calculate tumor volume according to the
Steel formula: V¼ LW2/2. Tumor growth curves were plotted for all
experimental groups.
2.3. Flow cytometry
The mice were sacriﬁced 20 days after the injection treatments.
The spleen was harvested and a splenocyte suspension was
prepared. Lymphocytes were isolated from this suspension by
density centrifugation over a Ficoll-Hypaque gradient (Lympho-
prep, Tian Jin Hao Yang Biological Manufacture, Tianjin, China). An
aliquot of 100 mL (1106 cells) was removed for dyeing, and 1 mL of
RNAiso Plus was added to the remainder for preservation at e80 C
for measurement of Foxp3 mRNA.
AMouseRegulatoryTcell stainingkit (ebioscience, SanDiego,USA)
was used for staining according to the manufacturer’s directions. In
brief, 100 mL of prepared cells (1106) was added to individual tubes
and surfacemoleculeswere stained using a standard procedure,with
a ﬂuorescein isothiocyanate-CD4 antibody and an allophycocyanin-
conjugated CD25 antibody. After washing with ﬂow cytometry
staining buffer, cells were treated with ﬁxation/permeabilization
working solution and washed once with 2 mL of permeabilization
buffer. After centrifugation, the supernatant was decanted and cells
were then stained with a phycoerythrin-conjugated Foxp3 antibody.Fig. 1. Tumor growth curves foFinally, cells were washed with 2 mL of permeabilization buffer,
resuspended in ﬂow cytometry staining buffer, and analyzed by ﬂow
cytometry (Beckman Coulter, Inc. California, USA).
2.4. Real-time RT-PCR
Spleen cells were isolated and preserved at e80 C. DNA-free
RNA templates were prepared using an RNA isolation kit (Shine-
gene Bio-Technologies, Shanghai, China). RNA concentrations and
quality were assessed using spectrophotometry at wavelengths of
260 and 280 nm. RNA was reverse-transcribed using a reverse
transcription kit (Takara Biotechnology, Dalian, China) according to
the manufacturer’s instructions. Real-time PCR assays were carried
out using a SYBR Premix Ex Taq kit (Takara Biotechnology). The
20-mL reaction system contained SYBR Premix Ex Taq (10 mL), ROX
Reference Dye II (0.4 mL), Foxp3 primers (50-CAG CTG CCT ACA GTG
CCC CTA G-30 and 50-CAT TTG CCA GCA GTG GGT AG-30, 0.4 mL each)
cDNA (2 mL) and dH2O (6.8 mL). PCR was performed on an ABI 7500
real-time PCR system (Applied Biosystems, Inc. California, USA).
The conditions were 95 C for 30 s, followed by 40 cycles at 95 C
for 5 s and 60 C for 34 s. HPRT (50-GTT GGA TAC AGG CCA GAC TTT
GTT G-30 and 50-GAT TCA ACT TGC TCT CAT CTT AGG C-30) was used
as a housekeeping gene for normalization of gene transcript levels.
2.5. Statistical analysis
Values are presented as mean standard deviation (SD).
Statistical analysis was performed using SAS version 8.0 software.
Student’s t test was used to examine the signiﬁcance of differences
between two groups. One-way analysis of variance (ANOVA), fol-
lowed by Dunnet’s test and a q test, was used to compare means
across multiple groups. A p value of < 0.05 was deemed to be
statistically signiﬁcant.
3. Results
3.1. Establishment of the tumor model
We applied a classic approach to establish a lung tumor model.
After injection of LLC cells, tumors were palpable on the 10th day
and could be seen by the naked eye on the 16th day. Tumor growth
curves are shown in Fig. 1. By contrast, the healthy groups showed
no changes. All the mice were killed 20 days after implantation
(Fig. 2) and splenocytes were isolated and used in experiments.
3.2. Changes in CD4þCD25þFoxp3þ Treg cells in spleen
The presence of CD4þCD25þFoxp3þ Treg cells was evaluated in
spleen for the six groups. As shown in Fig. 3 and Table 1, the ratior the experimental groups.
Fig. 2. A 4-week-old mouse sacriﬁced 20 days after injection. Tumor tissue in the left
forelimb is clearly evident.
Table 1
Comparison of the CD4þCD25þFoxp3þ/CD4þ cell ratio in spleen for the six groups.
Group Healthy Tumor
Young (4 w) 1.56 0.43 2.13 0.33
Middle-aged (6 m) 2.60 0.30* 3.25 0.42
Elderly (20 m) 3.71 0.40** 5.01 0.24
F values 47.70 108.29
P values <0.01 <0.01
* p¼ 0.0019 compared with the young healthy, ** p¼ 0.0082 compared with the
middle-aged healthy group.
Immunosenesence, Treg Cells and Tumors 189of CD4þCD25þFoxp3þ to CD4þ T cells was higher in the tumor
groups than in the healthy groups (t¼ 2.23, p¼ 0.032). The ratio
showed signiﬁcant differences among the healthy groups
(F¼ 47.70, p¼ 0.000). The MH group had a larger population of
CD4þCD25þFoxp3þ Treg cells in spleen compared to the YH group
(F¼ 53.35, p¼ 0.0019) and there was a signiﬁcant difference
between the EH andMH groups (F¼ 22.02, p¼ 0.0082). The highest
ratio was observed for the ET group.Fig. 3. Flow cytometric analysis of CD4þCD25þFoxp3þ Treg cells for the six groups. Represe
presented. The top row represents the healthy group, and the bottom row the tumor group3.3. Foxp3 mRNA expression levels in spleen
We investigated the levels of Foxp3 mRNA for the six groups.
Foxp3 mRNA ampliﬁcation was successfully performed by RT-PCR
(Fig. 4). Our results revealed differences among the six groups
(Fig. 5). Foxp3 mRNA levels were higher in the tumor compared to
the healthy groups (t¼ 3.26, p¼ 0.0042). Foxp3 mRNA levels in
spleen also increased with aging (F¼ 6.56, p¼ 0.0090); among the
healthy groups, levels were signiﬁcantly lower in the YH group
compared to the MH and EH groups. In agreement with its immune
function, changes in Foxp3 expression were consistent with varia-
tions in CD4þCD25þFoxp3þ Treg cells. Levels of Foxp3 mRNA were
affected by both age and tumor incidence, and the highest levels
were found in the elderly tumor group.
4. Discussion
The decrease in activation of cell-mediated immune responses
with aging may be related to the age-associated increase in tumor
incidence15e17. Besides CD28 and CD9518, Treg cells play a crucial
role. CD4þCD25þFoxp3þ Treg cells show high expression of cell-
surface molecules, including CD25, cytotoxic T-lymphocyte-asso-
ciated protein-4 (CTLA4) and glucocorticoid-induced tumor
necrosis factor receptor (GITR), and are characterized by expressionntative FACS analyses of CD4þ-cell-gated spleen preparations from the six groups are
.
Fig. 4. Gene ampliﬁcation for Foxp3 was carried out successfully by RT-PCR.
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(Foxp3)19,20. The constitutive expression of these factors is involved
in immunosuppression via several molecular mechanisms. CTLA4
interacts with CD80 and CD86 co-stimulatory molecules expressed
by antigen-presenting cells (APCs) and transduces a suppressive
signal21,22. Alternatively, it can directly mediate suppression by
triggering induction of the enzyme indoleamine 2,3-dioxygenase in
dendritic cells (DCs), which catalyzes the conversion of tryptophan
to kynurenine and other metabolites and has potent immunosup-
pressive effects on DCs. GITR is also present on the surface of
CD4þCD25þFoxp3þ Treg cells and its ligand is expressed on APCs
in mice and on plasmacytoid DCs in human; much evidence indi-
cates that it plays a role in suppressing effector T cells23,24. TheFig. 5. Foxp3 mRNA expression in spleen from the six groups. Data are mean SD
values after normalization to HPRT levels.transcription factor Foxp3 is a key player in conferring a suppres-
sive function to CD4þ T cells25,26. Retroviral transduction of Foxp3
upregulates Treg-associated molecules, including CD25, CTLA4 and
GITR, and suppresses gene transcription for cytokines such as IL-10
and TGF-b20. Besides mechanisms that depend on cellecell contact,
CD4þCD25þFoxp3þ Treg cells are involved in the maintenance of
downregulation of various immune responses by these cytokines in
an indirect manner27.
In the present study, we set up a Lewis lung tumor model in
mice of different ages and analyzed changes in the number of
CD4þCD25þFoxp3þ Treg cells and in Foxp3 mRNA levels in sple-
nocytes. Our results revealed signiﬁcant increases in both
parameters for tumor groups compared with the corresponding
healthy groups, which is consistent with previous studies28,29.
In the tumor groups, as a result of immunosuppression, the
increase in CD4þCD25þFoxp3þ Treg cells further supported tumor
immune evasion, whereas other studies demonstrated no corre-
lation between a higher number of CD4þCD25þFoxp3þ Treg cells
and suppression activity30,31. It is not known precisely why
CD4þCD25þFoxp3þ Treg cells are more numerous in mice with
tumors compared to their healthy counterparts. Research indi-
cates that natural CD4þCD25e T cells are converted to Treg cells by
IL-10 and TGF-b, which are tumor-derived soluble factors, under
tumor conditions32,33.
Results for the healthy groups revealed that the number of the
CD4þCD25þFoxp3þ Treg cells and Foxp3 mRNA levels increased
with aging. Despite a wealth of studies, there are no obvious
explanations of why the CD4þCD25þFoxp3þ Treg cell population
Immunosenesence, Treg Cells and Tumors 191increases with aging in healthy individuals and where it comes
from. Levels of both IL-1034 and TGF-b35 increase with aging, and
CD4þCD25þFoxp3þ Treg cells in elderly mice might be generated
from CD4þCD25eFoxp3e T cells, induced by changes in TGF-b and
IL-10 in a tumor environment. Another important explanation is
the existence of two subsets of CD4þCD25þFoxp3þ Treg cells with
very distinct fates, as conﬁrmed by Fisson et al36. One subset
exhibits a rapid proliferation rate characterized by a CD44high
phenotype, whereas the other subset does not divide but is long-
lived, and is characterized by a CD44int phenotype. These two
subsets might be relevant to the increase in number, but the
mechanism has not been completely clariﬁed.
Our experimental results reveal a close relationship between
changes in CD4þCD25þFoxp3þ Treg cells and aging and lung
tumor genesis and development. CD4þCD25þFoxp3þ Treg cells
play an important role in inhibiting immune responses, and
increases in this cell population with aging reduce the activity of
the immune system. Thus, the increase in CD4þCD25þFoxp3þ Treg
cells with aging may be a major factor in tumor incidence and the
damage caused by this increase may translate into a susceptibility
to tumorigenesis in the elderly. Evaluation of changes in
CD4þCD25þFoxp3þ Treg cells with aging to establish a normal
range for these cells at different ages could help in providing
a threshold target for immune crises in the elderly and in pre-
dicting tumor occurrence. Furthermore, if questions related to the
mechanism involved, such as immunological tolerance and accu-
mulation, can be answered, it should be possible to take effective
measures to interfere with this mechanism, which would open
new prospects for Treg-targeted immunomodulatory therapy.
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